Genmab — November 2020
-
Genmab price target raised to $45 from $42 at H.C. Wainwright
-
-
the 2nd PhIII Amivantamab trial also starts recruiting. Still waiting for that milestone... https://clinicaltrials.gov/ct2/history/NCT04538664?A=3&B=4&C=merged#StudyPageTop
-
Oral Cami at ASH - 474 Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma - https://ash.confex.com/ash/2020/webprogram/Paper137451.html
-
Danske Bank 5/11: "Valuation and estimate changes. Our updated SoTP points to a fair value of DKK2,467 (DKK2,306) per share. Adjustments reflect higher estimates/value for Tepezza, epocoritamab and GEN1046. We still include 50% probability of losing the daratumumab arbitrage dispute, which would have ~DKK200/share impact."
"5/11 09:29
" already had to laugh about that this morning and still laughing 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind